TP53 and cancer: While this might not be a viable option for the treatment of cancers that have both their copies of the RB1 gene inactivated, interestingly, pharmacological reactivation of another tumor suppressor p53 gene—Gendicine—was approved as a cancer gene therapy in China in 2003 for head and neck squamous cell carcinoma (see Section 5.2).